Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KEYNOTE-676 pembrolizumab + BCG in high-risk non-muscle invasive bladder cancer
NL-OMON55727Phase 3Recruiting
- Sponsor
- Merck & Co.
- Start
- Aug 2019
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 3, randomised trial in bladder cancer, transitional cell carcinoma (TCC) and non-muscle-invasive bladder cancer (NMIBC) comparing Pembrolizumab + BCG with BCG alone (2 arms). Primary endpoints: Complete response rate and Event-free survival. Started Aug 2019; status: recruiting.
02
Drugs
pembrolizumabbcg vaccine
03
Conditions
bladder cancertransitional cell carcinoma (TCC)non-muscle-invasive bladder cancer (NMIBC)
Beyond the preview
Go deeper on NL-OMON55727.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON55727.